COVID-19 (Coronavirus) Resources: COVID-19 Resources

For the latest information, residents of North Carolina should visit the
North Carolina Department of Health and Human Services and the Coronavirus Disease 2019 
section of the Centers for Disease Control and Prevention (CDC) website.

National News

North Carolina News

Research contributing to discoveries associated with COVID-19 has been growing on the UNC campus over the past year. To help increase visibility of this integral research and illustrate the extensive organizational collaborations that help move UNC research forward, a team from University Libraries – Health Sciences Library analyzed the COVID-19 research output of UNC Chapel Hill (UNC-CH) researchers. Between January 2020 and April 2021, a total of 782 UNC-CH researchers have authored 579 publications.

Access the full report and supplementary data at:

go.unc.edu/UNC-COVID19-Research.

The mask mandate does not apply to the following individuals:

• Anyone with a diagnosed medical or behavioral condition or disability, including difficulty breathing.
• Children under age 2.
• Children under 5 if a parent, guardian, or responsible person has been unable to place and maintain a face-covering safely on the child’s face.
• Anyone who is actively eating or drinking.
• Anyone who is seeking to communicate with someone who is hearing impaired in a way that requires the mouth to be visible.
• Anyone who is giving a speech or performance for a broadcast or to an audience where they maintain a distance of at least 20 feet is maintained from the audience.
• Anyone who is working alone in an individual office setting. Face coverings must be applied when in common areas such as breakrooms, hallways, restrooms, or other areas where additional persons may be encountered.
• Anyone who has determined the face covering is impeding the person’s visibility in the operation of equipment or a vehicle.

Information from OrangeCountyNC.gov

Everyone aged 6 months and up is eligible to receive a vaccine!

Find a COVID-19 vaccine:
Search vaccines.gov, text your ZIP code to 438829, or call 1-800-232-0233 to find locations near you.

Vaccine providers near Orange County NC:

• Orange County Health Department ― Visit their Get Your Shot page to sign up or call 919-913-8088 between 8:30 a.m. and 4:30 p.m. seven days a week. 
• UNC Health ― Visit the Get Vaccinated page or call 984-215-5485 between 8:00 a.m. and 5:00 p.m. Monday-Friday.
• Piedmont Health Services ― Visit the COVID-19 Testing and Vaccination page or call 919-545-3452.
• Hillsborough Pharmacy ― Visit their Home Page or call 919-245-1212.
• Duke Health ― Visit the COVID-19 Vaccines Update page to join the waiting list. If you are a Duke MyChart user, you can check Duke MyChart regularly to view appointment availability.
• Cone Health ― Visit the COVID-19 Vaccine Information page to join the waiting list.
• Durham Veterans Affairs Health Care System ― Call 919-286-0411 and dial 0 for the operator to schedule an appointment if you are a veteran at high risk or a veteran frontline essential worker. See the system’s website for more information. See the COVID-19 Vaccine for High Risk Veterans to see the listing of veterans eligible now for vaccination through the VA.

Data from Get Your Shot (Orange County NC)

Getting a vaccine booster shot

An updated COVID-19 booster is now available for people 12 and older, two months after they finish their primary series or any booster dose. It offers the most up-to-date protection against the latest Omicron variants. People age 5-11 can still get the original booster. The boosters, like all COVID-19 vaccines, are safe to get alongside the annual flu vaccine.

The Food and Drug Administration (FDA) has approved one drug, remdesivir (Veklury), to treat COVID-19.

Three anti-SARS-CoV-2 monoclonal antibody products currently have Emergency Use Authorizations (EUAs) from the Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in nonhospitalized patients with laboratory-confirmed SARS-CoV-2 infection who are at high risk for progressing to severe disease and/or hospitalization. The FDA also issued an EUA for high-titer COVID-19 convalescent plasma and only for the treatment of hospitalized patients with COVID-19 early in the disease course or hospitalized patients who have impaired immunity.

Monoclonal Antibody Treatments against Covid-19 are available at several UNC Health locations.

The criteria for patients to be considered for Monoclonal Antibody infusion therapy are:

• Test positive for SARS-CoV-2
• Have at least mild symptoms for no more than seven days
• Are age 65 plus or less than 65 but have a chronic health problem that puts you at risk for severe COVID-19. These include obesity, diabetes, lung disease, and heart disease, among others.

To find out if you are at high risk and eligible for COVID 19 Monoclonal Antibody infusion therapy, please call the UNC COVID Help Line at 888-850-2684, between 8 a.m. and 5 p.m., 7 days a week.

UNC is also part of a large study that is working to identify additional medications to treat COVID. The project is called Rise Above COVID or the ACTIV-2 Study is investigating medicines to see if they can help adults with COVID-19 recover more quickly.

You could be eligible to participate in the study if you tested positive for Covid-19 less than 10 days before, are not in the hospital, and have Covid-19 symptoms.

Drugs not recommended for treatment of Covid-19

The COVID-19 Treatment Guidelines Panel (the Panel) provides recommendations for using antiviral drugs to treat COVID-19 based on the available data.  The following drugs have been evaluated by the Panel and not recommended, or there is not enough evidence for the Panel to make a recommendation

Ivermectin

• There is insufficient evidence for the Panel to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.

Nitazoxanide

• The Panel recommends against the use of nitazoxanide for the treatment of COVID-19, except in a clinical trial (BIIa).

Hydroxychloroquine or Chloroquine and/or Azithromycin

• The Panel recommends against the use of chloroquine or hydroxychloroquine and/or azithromycin for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AIIa).

Lopinavir/Ritonavir and Other HIV Protease Inhibitors

• The Panel recommends against the use of lopinavir/ritonavir and other HIV protease inhibitors for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion 

UNC-Chapel Hill Updates

• UNC-Chapel Hill Campus Updates on COVID-19 (Carolina Together) 

Information on the University’s response to COVID-19, the Carolina Together Testing Program, and our COVID-19 Community Standards. 

Students, Faculty, Staff, and Researchers

• UNC Health COVID-19 Resources 

COVID-19 information as it relates to UNC Health and affiliated hospitals,
preparations, as well as tips for staying healthy

• Office of the Vice-Chancellor for Research Responds to COVID-19 

  Information for UNC-CH researchers about the impact of COVID-19

• UNC Gillings School of Public Health Coronavirus Resources 

  Links and information on the COVID-19 pandemic, including the work the Gillings School experts are doing

• UNC Institute for Global Health and Infectious Diseases

  COVID-19 information and resources for researchers and patients

North Carolina DHHS Dashboard

Situation Summary

CDC is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China and which has now been detected in almost 70 locations internationally, including in the United States. The virus has been named “SARS-CoV-2” and the disease it causes has been named “coronavirus disease 2019” (abbreviated “COVID-19”).

Public Health Information

Travel Information

Information on the Omicron Variant

Video: WHO's Science in 5 on COVID-19: Omicron variant

Podcast: BA.5: The Omicron Subvariant Driving Up Cases — And Reinfections

Podcast: When Should I Get my Omicron Booster Shot?